691 related articles for article (PubMed ID: 23800750)
1. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
2. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
3. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Woloshin S; Schwartz LM
JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of lorcaserin for the treatment of obesity.
Berlie HD; Hurren KM
Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690
[TBL] [Abstract][Full Text] [Related]
5. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
6. Phentermine/topiramate for the treatment of obesity.
Smith SM; Meyer M; Trinkley KE
Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
[TBL] [Abstract][Full Text] [Related]
7. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
8. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of lorcaserin in the management of obesity.
Hess R; Cross LB
Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
[TBL] [Abstract][Full Text] [Related]
10. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
11. Lorcaserin and phentermine/topiramate: two leaps forward in weight loss pharmacotherapy.
Hill LG
Ann Pharmacother; 2013 Dec; 47(12):1740. PubMed ID: 24396110
[No Abstract] [Full Text] [Related]
12. Long-term effects of weight-reducing drugs in people with hypertension.
Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
[TBL] [Abstract][Full Text] [Related]
13. Response to "lorcaserin and phentermine/topiramate: two leaps forward in weight loss pharmacotherapy".
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013 Dec; 47(12):1741. PubMed ID: 24311729
[No Abstract] [Full Text] [Related]
14. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.
Walter CP; Bleske BE; Dorsch MP
J Clin Pharm Ther; 2014 Oct; 39(5):475-84. PubMed ID: 24924286
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
[TBL] [Abstract][Full Text] [Related]
16. Topiramate + phentermine. An excessively dangerous appetite-suppressant combination.
Prescrire Int; 2013 Mar; 22(136):61-4. PubMed ID: 23593686
[TBL] [Abstract][Full Text] [Related]
17. Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
Grabarczyk TR
Pharmacotherapy; 2018 Jan; 38(1):19-28. PubMed ID: 29044720
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N
J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808
[TBL] [Abstract][Full Text] [Related]
19. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
20. Phentermine and topiramate extended release (Qsymia™): first global approval.
Cameron F; Whiteside G; McKeage K
Drugs; 2012 Oct; 72(15):2033-42. PubMed ID: 23039320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
